Studybox Research Dual Submission Studies
Fentanyl Urine Screen
One integrated study supporting both 510(k) clearance and CLIA waiver.
Studybox
Dual Submission Studies
Fentanyl is not detected by traditional opiate immunoassays, which target morphine-like structures, and the rise of illicitly manufactured fentanyl created demand for dedicated screens. The clinical study follows the drugs-of-abuse model, mass spectrometry confirmation on every specimen and agreement by concentration stratum around the cutoff, with two fentanyl-specific complications: fentanyl is rapidly metabolized so that norfentanyl often predominates in urine, and the illicit supply contains analogs whose cross-reactivity with the antibody varies.
The comparator definition therefore matters. A device that detects fentanyl but not norfentanyl will miss specimens from people whose last use was more than a day earlier, and the protocol should state whether agreement is assessed against fentanyl, norfentanyl or either. Positives come from emergency departments and treatment programs, and legitimately prescribed fentanyl (patches, perioperative use) produces true positives that labeling must address.
- Analyte
- Fentanyl and its primary metabolite norfentanyl at a defined cutoff concentration
- Therapeutic area
- Drugs of Abuse
- Specimens
- Urine
- Intended-use settings
- physician office, urgent care, emergency department, home use
- Operators
- Non-laboratory staff in emergency departments, treatment programs, urgent care and physician offices with waived certificates; lay users for over-the-counter versions.
- Comparator
- Typically LC-MS/MS quantitation of fentanyl and norfentanyl, with results classified relative to the device cutoff.
Dual Submission specifics
What Changes for This Assay on This Pathway.
- A single study at waived sites with confirmatory LC-MS/MS on every specimen supports both components; the stratified agreement analysis serves the 510(k) half and untrained operator agreement serves the waiver half.
- Over-the-counter versions add a lay user arm; harm-reduction fentanyl test strips used to check drug samples rather than urine are a different product and should not be confused with the clinical device in study planning.
- A pre-submission is typical for a newer analyte to agree on cutoff, confirmatory target and analog panel.
Endpoints the study must support
- Percent agreement with LC-MS/MS stratified by concentration relative to the cutoff
- Precision near the cutoff using characterized or spiked specimens
- Cross-reactivity with fentanyl analogs and structurally unrelated opioids, and interference from common medications
- Untrained operator and, for over-the-counter claims, lay user agreement
Enrollment realities
Driven by confirmed positives near the cutoff, which are uncommon prospectively because active-use specimens are typically far above it; characterized specimens fill the gap. Emergency department and treatment program sites supply high-concentration positives quickly.
How Studybox runs it
Pre-Qualified Sites, Embedded Coordinators.
Waiver evidence depends on genuine intended-use operators in genuine waived settings. Our network of 100+ pre-qualified urgent care, physician office, and point-of-care sites already runs IVD protocols, so operator recruitment and site activation don't start from zero. How we run dual submission studies →
Same assay, other pathways
Relevant FDA guidance
- Recommendations for Dual 510(k) and CLIA Waiver by Application Studies
- Recommendations for Clinical Laboratory Improvement Amendments of 1988 (CLIA) Waiver Applications for Manufacturers of In Vitro Diagnostic Devices
- Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program
FAQ
Fentanyl Urine Screen Study Questions.
01 Who operates the fentanyl urine screen in a dual submission study?
Non-laboratory staff in emergency departments, treatment programs, urgent care and physician offices with waived certificates; lay users for over-the-counter versions.
02 What is the comparator for a fentanyl urine screen study?
Typically LC-MS/MS quantitation of fentanyl and norfentanyl, with results classified relative to the device cutoff.
03 What drives enrollment for a fentanyl urine screen study?
Driven by confirmed positives near the cutoff, which are uncommon prospectively because active-use specimens are typically far above it; characterized specimens fill the gap. Emergency department and treatment program sites supply high-concentration positives quickly.
Let's talk IVD research
Planning a fentanyl urine screen study?
Tell us the intended use and setting. We'll come back with a site plan, operator strategy, and a realistic activation timeline for the dual submission pathway.